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Proopiomelanocortin Signaling 
System Is Operating in Mast Cells
Andrzej T. Slominski1
The proopiomelanocortin (POMC) system is the central coordinator of the 
systemic endocrine responses to sustained stress. It has been recently dis-
covered that mast cells also display regulated production of POMC peptides. 
Since at the tissue level mast cells integrate stress responses into the neu-
roimmune regulatory network, it is likely that the POMC system is involved in 
mast cells’ functions in tissue homeostasis.
Journal of Investigative Dermatology (2006) 126, 1934–1936. doi:10.1038/sj.jid.5700342
The proopiomelanocortin system
Proopiomelanocortin (POMC) is pre-
dominantly produced in the anterior 
pituitary, where it is a mediator in the 
hypothalamic–pituitary–adrenal axis, 
the main adaptive response to sys-
temic stress. The hypothalamic–pitu-
itary–adrenal axis is activated by the 
stress-induced production and release 
of hypothalamic corticotropin-releasing 
hormone (CRH), which, in turn, acti-
vates the anterior pituitary CRH recep-
tor type 1 to stimulate production and 
release of POMC-derived ACTH. ACTH 
directly stimulates adrenocortical pro-
duction and secretion of cortisol (in 
humans) or corticosterone (in rodents); 
these steroids counteract the effects of 
the stressor and suppress the hypotha-
lamic–pituitary–adrenal axis through 
negative-feedback inhibition. Besides 
the pituitary, the POMC system is also 
expressed in the brain and peripheral 
tissues that include the skin (Slominski 
et al., 2000). The POMC gene contains 
three exons, separated by two introns 
that are spliced out in the pituitary 
and brain to generate POMC mRNA 
of approximately 1.1 kb (Slominski et 
al., 2000; Smith and Funder, 1988). 
Shorter and longer POMC transcripts 
have also been found predominantly 
in extrapituitary tissues, and the size 
heterogeneity has been explained by 
alternative splicing, variation in the 
length of the poly(A)+ tail, or use of 
alternate transcription initiation sites. 
Moreover, smaller mRNAs are also trans-
latable despite lack of the signal peptide 
sequence (Slominski et al., 2000).
POMC yields different neuropep-
tides (for example, ACTH, α-melano-
cyte-stimulating hormone (α-MSH), 
γ1-3-MSH, β-MSH, and β-endorphin), 
generated through processing mecha-
nisms that are cell and tissue specific, 
including post-translational modifi-
cations of the POMC precursor with 
endo- and exopeptidase cleavage, 
amidation, and acetylation (Smith and 
Funder, 1988). In general, the POMC 
precursor is selectively cleaved at the 
dibasic amino acid residues by pro-
hormone convertase 1 (PC1) and PC2 
(and perhaps furin convertase (FC) 
and paired basic amino acid con-
verting enzyme 4 (PACE4)) in a pro-
cess affected by O-glycosylation of 
the prohormone (Smith and Funder, 
1988; Wilkinson, 2006). PC1 sequen-
tially cleaves POMC to produce a 16 
kilodalton N-terminal peptide, a join 
peptide, and the carboxy-terminal 
peptides ACTH and β-LPH (β-lipotro-
pin) with some β-endorphin (Smith 
and Funder, 1988). PC2 then cleaves 
ACTH to generate ACTH(1–17) CLIP; 
β-LPH to generate β-endorphin and 
γ-LPH (further cleaved to β-MSH); 
and pro-γ-MSH to generate γ1-3-MSH 
(Smith and Funder, 1988). Sequential 
actions of carboxypeptidase E on 
ACTH(1–17), together with C-termi-
nal peptide amidation by peptidyl 
α-amidating mono-oxygenase, and 
α-N-acetylation at the N-terminus 
produce mature α-MSH (Wilkinson, 
2006). In addition, segments of POMC 
can undergo differential N- and O-
glycosylation, sulfatation and phos-
phorylation, and post-translational 
modification to generate N-acetylated 
and truncated forms of β-endorphin, 
truncated forms of ACTH, and variant 
forms of α-MSH (Smith and Funder, 
1988; Wilkinson, 2006).
POMC-derived peptides (and per-
haps POMC precursor proteins them-
selves) can act as neurotransmitters, 
neurohormones, hormones, cyto-
kines, growth factors, and immuno-
modulators, depending on the site 
of production, form of delivery, and 
target-cell function. In skin cells the 
peptides are involved in melanin pig-
mentation (predominantly ACTH and 
α-MSH), immune activity (predomi-
nantly immunosuppression), functions 
of adnexal structures (hair follicle, 
sebaceous and eccrine glands), secre-
tory activities, differentiation level 
and potential, migratory capabilities, 
and proliferation (Slominski, 2005; 
Slominski et al., 2004; Slominski et al., 
2000). POMC peptide receptors have 
been shown for the main skin cellular 
populations, including keratinocytes, 
melanocytes, fibroblasts, sebocytes, 
and immune cells (Slominski, 2005; 
Slominski et al., 2000). It has been 
therefore proposed that the cutaneous 
POMC system, being highly organized 
and encoding mediators and receptors 
coupled differentially to signal trans-
duction systems and endowed with 
stress-neutralizing activity, is addressed 
at maintaining skin integrity to restrict 
stress-dependent disruptions of inter-
nal homeostasis with potential effects 
on global homeostasis (Slominski et 
al., 2004; Slominski and Wortsman, 
2000; Slominski et al., 2000).
Mast cells
Mast cells are recognized for their 
pathogenic role in production of 
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allergic and anaphylactic reactions, 
especially in the skin. Mast cells can 
rapidly induce multiple tissue effects 
that include vasodilation, angiogen-
esis, and proinflammatory activities; 
mast cells have also been implicat-
ed in innate immunity and autoim-
mune processes (Theoharides and 
Cochrane, 2004; Theoharides et al., 
2004). The above actions are related 
to the capacity of mast cells to synthe-
size and secrete over 50 biologically 
powerful molecules such as hista-
mine, heparin, kinins, neuropeptides 
(including vasoactive intestinal pep-
tide), proteases (chymase and pre-
formed tryptase), chemoattractants, 
cytokines (tumor necrosis factor-α and 
interleukin-6 in particular), growth 
factors, leukotrienes, prostaglandins, 
nitric oxide, stem-cell factor, and vas-
cular endothelial growth factor. It is of 
further interest that human mast cells 
also produce and release relatively 
large amounts of CRH and the relat-
ed urocortin peptide in response to 
chemical, physical, or psychological 
stimulation; mast cells also express 
corresponding CRH receptors (Paus et 
al., 2006; Theoharides et al., 2004).
Remarkably, mast cells display high 
selectivity in determining the media-
tors to be released, depending prima-
rily on the pathophysiological con-
text of this process (Paus et al., 2006; 
Theoharides and Cochrane, 2004; 
Theoharides et al., 2004). Also specif-
ic is the cellular structure affected; in 
anaphylactic reactions, thus, they can 
release their content through typical 
degranulation of the majority of secre-
tory granules, or through secretion 
of the content of individual granules, 
or even by releasing selective media-
tors without degranulation (Paus et 
al., 2006; Theoharides and Cochrane, 
2004). As mast cells are located 
perivascularly in close proximity 
to neurons, the existence of a func-
tional association between mast cells 
and nerve cells has been postulated 
(Paus et al., 2006; Theoharides and 
Cochrane, 2004; Theoharides et al., 
2004). Indeed, mast cells can be acti-
vated by antidromic nerve stimulation 
(for example, of the trigeminal nerve 
or the cervical ganglion) to secrete 
neuropeptides, and therefore release 
of substance P or CRH from sensory 
nerves to stimulate mast-cell secretion 
could occur in vivo (Paus et al., 2006; 
Theoharides and Cochrane, 2004; 
Theoharides et al., 2004). Thus, a role 
for mast cells has been proposed as 
coordinators of immune, neural, and 
endocrine activities at the central and 
peripheral levels (Paus et al., 2006; 
Theoharides and Cochrane, 2004; 
Theoharides et al., 2004). In the skin, 
mast cells would coordinate local 
cutaneous neuroimmune responses 
(Paus et al., 2006; Theoharides and 
Cochrane, 2004).
The POMC system in the skin mast cells
Artuc et al. (2006, this issue) dem-
onstrate that human skin mast cells 
express the POMC gene and protein, 
and they provide evidence supporting 
the further processing to the secre-
tory molecule α-MSH. Moreover, the 
addition of anti-IgE antibody signifi-
cantly reduces intracellular α-MSH, 
while increasing its extracellular lev-
els, indicating IgE-mediated secretion 
of the neuropeptide. Furthermore, 
because skin mast cells co-express the 
PC1, PC2, and FC genes, they have 
the potential to fully express the enzy-
matic machinery necessary to pro-
cess POMC to α-MSH. These findings 
complement previous reports of ACTH 
antigen expression in mast cells and 
are consistent with the ability of α-
MSH to stimulate the release of hista-
mine (Artuc et al., 2006). As a clinical 
implication, the work may explain a 
well-known phenomenon of increased 
pigmentation of lesional skin in urti-
caria pigmentosa. From the experi-
mental point of view, these findings 
implicate mast cell-derived α-MSH in 
the autocrine and paracrine regulation 
of local immune activity and inflam-
matory and allergic responses.
An immediate challenge would be 
to define, within the context of expect-
ed actions, the precise mechanism(s) 
regulating POMC expression, process-
ing in mast cells, and release of pep-
tide products from mast cells. Indeed, 
elucidation of both ligand identity and 
time dependence for POMC system 
activation should clarify the function-
al organization of the signaling axis 
involving ligand → POMC expression 
→ processing → release of final prod-
ucts. Thus, if the predominant final 
product were ACTH, POMC activa-
tion could result in local stimulation of 
cortisol production (Slominski, 2005), 
whereas if it were instead α-MSH, the 
local actions on melanin pigmentation 
would predominate (Slominski et al., 
2004). In the latter case, modifications 
of α-MSH molecules could be involved, 
playing perhaps important roles in phe-
notypic specificity or in attenuation 
of variant action (Wilkinson, 2006). 
Furthermore, the remaining possibility 
of peptide co-secretion would result in 
further widening of the range of regu-
lators for mast-cell responses, with the 
inherent possibility of enhanced “fine-
tuning” in the local reaction to cuta-
neous stressors. Lastly, from the 
evolutionary point of view, the findings 
of Artuc et al. (2006) provide addition-
al evidence strengthening the concept 
of conservation of the central stress 
response algorithm at distant, local 
levels (Paus et al., 2006; Slominski, 
2005; Slominski and Wortsman, 2000; 
Slominski et al., 2000; Theoharides et 
al., 2004).
CONFLICT OF INTEREST
The author states no conflict of interest.
ACKNOWLEDGMENTS
We thank Dr. Jacobo Wortsman for helpful 
discussions. Support of the United States 
National Institutes of Health (grants AR047079 
and AR052190 to A.T.S.) is also acknowledged.
REFERENCES
Artuc M, Böhm M, Grützkau A, Smorodchenko A, 
Zuberbier T, Luger T et al. (2006) Human mast 
cells in the neurohormonal network: expression 
of POMC, detection of precursor proteases, 
and evidence for IgE-dependent secretion of 
α-MSH. J Invest Dermatol 126:1976–81
Paus R, Theoharides TC, Arck PC (2006) 
Neuroimmunoendocrine circuitry of the 
‘brain-skin connection’. Trends Immunol 
27:32–9
Slominski A (2005) Neuroendocrine system of 
the skin. Dermatology 211:199–208
Slominski A, Tobin DJ, Shibahara S, Wortsman J 
|
 
These fi ndings 
implicate mast cell-
derived α-MSH in the 
autocrine and paracrine 
regulation of local 
immune activity.
COMMENTARY
1936 Journal of Investigative Dermatology (2006), Volume 126
(2004) Melanin pigmentation in mammalian 
skin and its hormonal regulation. Physiol Rev 
84:1155–228
Slominski A, Wortsman J (2000) 
Neuroendocrinology of the skin. Endocr Rev 
21:457–87
Slominski A, Wortsman J, Luger T, Paus R, 
Solomon S (2000) Corticotropin releasing 
hormone and proopiomelanocortin 
involvement in the cutaneous response to 
stress. Physiol Rev 80:979–1020
Smith AI, Funder JW (1988) Proopiomelanocortin 
processing in the pituitary, central nervous 
system, and peripheral tissues. Endocr Rev 
9:159–79
Theoharides TC, Cochrane DE (2004) Critical role 
of mast cells in inflammatory diseases and the 
effect of acute stress. J Neuroimmunol 146:1–12
Theoharides TC, Donelan JM, Papadopoulou N, 
Cao J, Kempuraj D, Conti P (2004) Mast cells 
as targets of corticotropin-releasing factor 
and related peptides. Trends Pharmacol Sci 
25:563–8
Wilkinson CW (2006) Roles of acetylation and 
other post-translational modifications in 
melanocortin function and interactions with 
endorphins. Peptides 27:453–71
